IOVA News and Press, Iovance Biotherapeutics Inc.

2024-05-13 11:06:56 ET Summary Iovance's new TIL therapy, Amtagvi, has launched but with modest Q1 revenue amidst substantial operational costs. Enrollment has reached over 100 patients, showing a promising start, although logistical challenges persist. Financially, Iovance ha...

2024-05-11 10:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The biotech sector holds some of the most promising and popular stocks on the market. With the promise of breakthrough treatments that generate billions of dollars annually, investors always lo...

2024-05-10 14:40:31 ET Summary Iovance Biotherapeutics reported its Q1 2024 earnings yesterday. The company made a net loss of $(113m), or $(0.42) per share. Iovance secured a historic approval for a first solid tumor targeting cell therapy in mid-Feb, triggering overnight gains o...

2024-05-10 14:03:28 ET Iovance Biotherapeutics (NASDAQ: IOVA) shares are down to the tune of 18% today following Thursday evening's release of its first-quarter numbers. The sell-off clearly suggests investors didn't like everything they heard. The knee-jerk response to the news, ho...

2024-05-09 20:40:27 ET Iovance Biotherapeutics, Inc. (IOVA) Q1 2024 Results Conference Call May 09, 2024 04:30 PM ET Company Participants Sara Pellegrino - Senior Vice President, Investor Relations & Corporate Communications Dr. Fred Vogt - Interim President &...

2024-05-09 16:03:02 ET More on Iovance Biotherapeutics Iovance Biotherapeutics: Riding The Favorable Moment Could Bring Excellent Results Iovance Biotherapeutics: Initial Amtagvi Launch In Focus Iovance Biotherapeutics, Inc. (IOVA) Q4 2023 Earnings Call Transcript ...

Strong Momentum for Amtagvi™ (Lifileucel) U.S. Launch Following U.S. Food and Drug Administration (FDA) Approval 100+ Amtagvi Patients Enrolled Across More Than 40 Current Authorized Treatment Centers (ATCs), with ~50 Total ATCs On Track by End of May and 70+ Total ATCs by Year...

AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...

2024-05-08 17:35:55 ET Major earnings expected after the bell on Thursday include: Unity Software ( U ) Main Street Capital Corporation ( MAIN ) Marathon Digital Holdings ( MARA ) Wheaton Precious Metals Corp. ( WPM ) Blink Charging Co. ( BLNK ) ...

2024-05-06 09:28:42 ET Iovance Biotherapeutics (NASDAQ: IOVA) stock price has rebounded sharply in the past few days as traders wait for the upcoming financial results. It rose by almost 6% on Friday and by over 3% on Monday. It has jumped to $14, almost 28% above its lowest point in Ap...